Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial

Ruqaiya M Al Balushi,1 Jennifer D Paratz,1,2 Jeremy Cohen,1,2 Merrilyn Banks,3 Joel Dulhunty,1,2 Jason A Roberts,1,2 Jeffrey Lipman1,2

ABSTRACT
Background: Trauma patients are characterised by alterations in the immune system, increased exposure to infectious complications, sepsis and potentially organ failure and death. Glutamine supplementation to parenteral nutrition has been proven to be associated with improved clinical outcomes. However, glutamine supplementation in patients receiving enteral nutrition and its best route are still controversial. Previous trials have been limited by a small sample size, use of surrogate outcomes or a limited period of supplementation. The aim of this trial is to investigate if intravenous glutamine supplementation to trauma patients receiving enteral nutrition is associated with improved clinical outcomes in terms of decreased organ dysfunction, infectious complications and other secondary outcomes.

Methods/design: Eighty-eight critically ill patients with multiple trauma receiving enteral nutrition will be recruited in this prospective, triple-blind, block-randomised, placebo-controlled clinical trial to receive either 0.5 g/kg/day intravenous undiluted alanyl-glutamine or intravenous placebo by continuous infusion (24 h/day). Both groups will be receiving the same standard enteral nutrition protocol and the same standard intensive care unit care. Supplementation will continue until discharge from the intensive care unit, death or a maximum duration of 3 weeks. The primary outcome will be organ-dysfunction evaluation assessed by the pattern of change in sequential organ failure assessment score over a 10-day period. The secondary outcomes are: the changes in total sequential organ failure assessment score on the last day of treatment, infectious complications during the ICU stay, 60-day mortality, length of stay in the intensive care unit and body-composition analysis.

Discussion: This study is the first trial to investigate the effect of intravenous alanyl-glutamine supplementation in multiple trauma patients receiving enteral nutrition on reducing severity of organ failure and infectious complications and preservation of lean body mass.

ARTICLE SUMMARY

Article focus
- Glutamine supplementation has demonstrated improved clinical outcomes in patients receiving parenteral nutrition. However, its effect and the best route of administration remain inconclusive for patients receiving enteral nutrition.
- Previous trials for patients receiving enteral nutrition had a number of limitations.

Key messages
This proposed research with other worldwide trials will have implications in improving the practice of glutamine supplementation in critically ill patients.

The results of this trial will provide pilot data for a large multicentre trial to investigate the effect of intravenous glutamine supplementation in multiple trauma patients receiving enteral nutrition on infectious complications and mortality.

Strengths and limitations of this study
- This is the first trial to investigate the effect of intravenous glutamine supplementation in trauma patients receiving enteral nutrition on organ failure, infectious complications and body composition.
- Supplementation is continued as long as the patient is in the intensive care unit or to a maximum duration of 21 days.
- This is a single-centre trial, so it is not powered for number of affiliations see end of article.

Correspondence to Ruqaiya M Al Balushi; ruqaiya.albalushi@uqconnect.edu.au

Trial registration number: This trial is registered at http://www.clinicaltrials.gov. NCT01240291.
BACKGROUND
Multiple trauma is life-threatening, not only from the initial trauma insult alone, but also from the subsequent massive immunological dysfunctions and metabolic alterations.1 Multiple trauma is characterised by impairment in the immune response2 3 that is associated with an increased rate of infectious complications and death.4 5 In fact, infectious complications in critically ill patients remain a serious problem worldwide and are independently associated with higher hospital mortalities.6

METABOLIC RESPONSE TO CRITICAL ILLNESS
Critical illness exhibits a metabolic response that is characterised by hypermetabolism,7 insulin resistance associated with hyperglycaemia,8 9 lipolysis10 and accelerated protein catabolism7 that might reach up to 2% per day.11 In critically ill patients, net protein catabolism is accelerated,12–16 despite vigorous nutritional support and increased protein intake.13 14 Loss of lean body mass during critical illness is considered a major clinical problem that delays wound healing and recovery. In parallel, there is a depletion of glutamine levels in muscle.15 16 Although glutamine production is increased in critically ill patients, it is not sufficient to maintain intracellular levels of glutamine in muscle.17

GLUTAMINE SUPPLEMENTATION
Glutamine, traditionally considered as a non-essential amino acid under normal physiological conditions, has received considerable attention in becoming ‘conditionally indispensable’ during catabolic states such as major surgery and critical illness.18 Under stress and catabolic conditions such as major surgery,19 burn injury20 21 and multiple trauma,22–25 there is a severe depletion of glutamine levels in plasma. It has been reported that a low plasma glutamine level at intensive-care unit (ICU) admission is an independent risk factor for mortality.26

In the past two decades, numerous trials have documented beneficial effects of glutamine supplementation in critically ill patients.23 27–35 There is good evidence that glutamine supplementation in critically ill patients receiving parenteral nutrition is associated with improved clinical outcomes in terms of improved survival rate, decreased infections, costs and reduced hospital length of stay.27–31 Indeed, currently glutamine supplemented parenteral nutrition is the standard of care in critical illness.37–39 However, there are also recent trials that failed to demonstrate any beneficial effect of supplemented total parenteral nutrition.40 41 It has been reported that intravenous glutamine supplementation in surgical patients counteracts muscle glutamine depletion and can enhance the rate of muscle protein synthesis.42 43 However, in critically ill patients, although intravenous glutamine supplementation increased plasma glutamine levels, muscle glutamine concentration and muscle protein synthesis were only marginally influenced.44 45 This might be explained by the increased demand on glutamine in critically ill patients.

Glutamine supplementation in patients receiving enteral nutrition and its best route are still debated. Despite the numerous numbers of clinical trials that have been conducted to investigate the beneficial effects of glutamine supplementation in patients receiving enteral nutrition,32 35 46–50 the results are conflicting and inconclusive. Enteral nutrition is advocated in critically ill and trauma patients when the gastrointestinal tract is functioning in terms of reduced infectious complications.51–53 Therefore, enteral glutamine supplementation is attractive when tube feeding is carried out.54 However, in clinical practice with enteral nutrition, especially in critically ill patients, there is a clear difference between what is targeted and what actually could be delivered.55 It has been documented that the systemic bioavailability of glutamine via the enteral route is less than via the intravenous route.55 To overcome the problem of not reaching the target dose by the enteral route, and the possibility of altered gut-absorption capacity, a number of trials investigated the effect of intravenous glutamine supplementation in patients receiving enteral nutrition.56–59 However, these trials were: pilot studies, including both enteral- and parenteral-nutrition-receiving patients, and most measured surrogate outcomes.

As primary outcomes in nutritional intervention trials, infectious complications and mortality require a large number of participants.60–62 Therefore, critical illness scores that relate to mortality and infectious morbidity end points have been considered as an alternative outcome measure.60 61 Multiple organ failure is considered as a reliable predictor of mortality in critically ill patients.65 Since mortality is not a feasible endpoint in a single-centre trial, we decided to use sequential organ failure assessment (SOFA) score as a surrogate primary outcome measure.

The aim of this study is to determine whether providing intravenous alanyl-glutamine (0.5 g/kg/day) will be associated with improved clinical outcomes in terms of reduced severity of organ dysfunction and reduction in infectious morbidity in mechanically ventilated trauma patients receiving enteral nutrition. To our knowledge, no study has investigated the effect of intravenous alanyl-glutamine supplementation in multiple trauma patients receiving enteral nutrition on organ dysfunction and infectious morbidity. In addition, our study is the first clinical trial to investigate the effect of intravenous alanyl-glutamine supplementation on body composition in multiple trauma patients.

RESEARCH QUESTIONS
1. What is the effect of intravenous alanyl-glutamine supplementation compared with placebo in multiple trauma patients receiving enteral nutrition on organ dysfunction; Sequential Organ Failure Assessment (SOFA); (ΔSOFA)?
2. What is the effect of intravenous alanyl-glutamine supplementation compared with placebo in multiple trauma patients receiving enteral nutrition on infectious morbidity, 60-day mortality, length of stay in ICU, length of stay in hospital, number of days on mechanical ventilation, number of days of antibiotic use during ICU stay, and fat-free mass and fat percentage as a measure of body composition?

METHODS/DESIGN

The GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT) Study is a prospective, interventional, single-centre, concealed block-randomisation, triple-blinded (subject, care givers, outcome assessor), placebo-controlled trial (figure 1). The study has been designed with the Consolidated Standards for Reporting of Trials guidelines.64 The trial will be conducted in a tertiary university-affiliated intensive-care unit at Royal Brisbane and Women’s Hospital (RBWH), Brisbane, Australia. It has been approved by the University of Queensland Human Ethics Committee (Project No 2010001359) and the Human Ethics Committee of RBWH (Protocol No HREC/10/QRBW/131). Dipeptiven is unregistered in Australia, so for the purpose of this trial, clinical trial notification (CTN) has been obtained from the Therapeutic Goods Administration of Australia (TGA) (trial no 2010/0623). The patients will be enrolled in the study after informed consent has been obtained from next of kin.

The duration of supplementation in many previous trials was short (eg, 3–7 days), which might explain why no effect has been found in many of them. In addition, it has been considered that a minimum of 5 days of glutamine supplementation is necessary to show an effect on infectious complications.23 Therefore, we decided to continue supplementation for a longer period of time (ie, 3 weeks) as long as the patient remained in the ICU. Also, the maximum approved dose (0.5 g/kg/day alanyl-glutamine) to ensure maximal beneficial effect will be given.

SELECTION OF PARTICIPANTS

Inclusion criteria

The inclusion criteria are: age 18–85 years, patients admitted with a diagnosis of multiple trauma requiring mechanical ventilation, patients requiring enteral feeding for >48 h, expected length of stay in the ICU >48 h, functional access for enteral tube feeding and central access for administration of test solution, and negative β HCG (pregnancy test) in females (18–60 years).

Exclusion criteria

The exclusion criteria are: pregnancy, age <18 years, significant hepatic failure (patients with Childs C Cirrhosis), severe renal failure (glomerular filtration rate (<GFR) <50 ml/min), patients with inborn errors of amino-acid metabolism (eg, phenylketonurea), patients with metabolic acidosis (pH<7.35), not expected to be in the ICU >48 h (owing to imminent death), unable to tolerate enteral nutrition within 72 h, enrolment in other ICU intervention study if contraindicated, patients in whom parenteral nutrition is required from the outset or an absolute contraindication to enteral nutrition.

Randomisation

Participants will be randomised by opaque sealed envelope after enrolment. Numbers in the envelope have been generated by a computer-generated randomisation (http://www.randomization.com) table based on blocks of four to assign patients to treatment group or placebo group. The solutions will be prepared by the unblinded pharmacist (JR) and placed into identical infusion bags. The study solutions will be indistinguishable by colour, smell or taste.

INTERVENTION

Intervention arm

This group (randomly allocated) will receive intravenous alanyl-glutamine (0.5 g/kg body weight/day; 2.5 ml/kg body weight; ie, 0.35 g L-glutamine/kg body weight/day; Dipeptiven, Fresenius-Kabi, Bad Homburg, Germany) by continuous infusion (24 h/day) through a dedicated lumen via central venous access until discharge from the ICU, death, or for a maximum duration of 3 weeks. Dipeptiven is a solution (20%, w/v) of glutamine-containing dipeptide, N(2)-L-alanyl-L-glutamine. The normal body weight will be calculated according to Broca’s formula (normal body weight (kg)=patient height (cm)–100). This formula has been used by the ‘Reducing Deaths Due to Oxidative Stress’ study,65 and we elected to use it, as each patient’s height can be accurately measured. This group represents the treatment group. It has been advised that for the intervention nutrient to have beneficial efficacy, it should be administered as soon as possible after the injury.66 Therefore, the intervention solution will be initiated within 24–48 h after admission to the ICU and independent from the start of enteral nutrition (ie, supplementation will be started even before enteral nutrition starts).

Figure 1 Trial flow chart. IV, intravenous.
Control arm (placebo)
This group will receive intravenous placebo (normal saline; 0.9% NaCl; 2.5 ml/kg/day) by continuous infusion (24 h/day) through a dedicated lumen via central venous access until discharge from the ICU, death or for a maximum duration of 3 weeks.

All patients in both groups will receive standard, polymeric, high-caloric, high-protein enteral formula (1.2 kcal/1 ml; 12 g/l fibre; 55.5 g/l protein) and start at a rate of 40 ml/h according to the standard feeding protocol followed at RBWH.67 Enteral nutrition will be targeted to be initiated within 24–48 h, and the aim is to reach the target goal by day 3. If enteral nutrition has failed by day 3 post-ICU admission, parenteral nutrition will be started. It will not be initiated until all efforts to maximise enteral nutrition have been attempted, including motility agents and small-bowel feeding. If the subject continues to require enteral nutrition after 3 weeks or is discharged from the ICU, intravenous supplementation will be discontinued.

ENDPOINTS
Primary endpoints
Outcome measures will be taken by a blinded investigator. The primary outcome measure will be taken daily until discharge from the ICU, death or maximum duration of 10 days.

The primary endpoint is organ dysfunction evaluation assessed by the pattern of change in SOFA score over a period of 10 days. This will be analysed by comparing daily measured SOFA score subtracted from the baseline SOFA score (the delta daily total SOFA score) each day and calculating the regression coefficients for each resulting slope. The regression coefficients for the two groups will be compared with a Student t test as described by Beal et al.60

Secondary endpoints
The secondary outcomes are:
1. The change in total SOFA score on the last day of treatment, where the change in total SOFA score = baseline total SOFA score − last day of treatment total SOFA score. A higher number indicates an improvement compared with baseline.
2. Infectious morbidity (ventilator-associated pneumonia, urinary-tract infection, bloodstream infection, sinusitis, abdominal infection, sepsis) during the ICU stay or a maximum duration of 3 weeks. We will use standardised definitions to limit bias, so modified criteria of the Centre for Disease Control definitions will be followed.68
4. Length of stay in the ICU.
5. Length of stay in hospital (if delayed discharge owing to placement problems, will record from the date the patient is regarded as fit for discharge by medical staff).
6. Number of ventilator-free days (VFD). A ventilator-free day is defined as a 24 h period from midnight to midnight that a patient is breathing independently of the ventilator. However, a day with tracheotomy cannula in place but without mechanical ventilation before extubation will be counted as a ventilator-free day.
7. Number of days of antibiotic use during the ICU stay.
8. Fat-free mass and fat percentage as a measure of body composition during an ICU day.

Routine ICU blood tests will be recorded daily until discharge from the ICU or a maximum duration of 3 weeks, including white-blood-cell count, platelets, neutrophils, lymphocytes, monocytes, urea, creatinine, protein and albumin. In 15 patients, C-reactive protein will be measured as a marker of inflammation and plasma amino acids profile will be measured and at baseline, day 7, day 14 and day 21.

STATISTICS
Sample-size calculation
Statistical analysis for the primary point (the delta daily total SOFA score plotted each day over 10 days) would involve linear regression power analysis where y = delta daily total SOFA score and x = day of measurement. Linear regression would therefore provide the slope of line, which is similar to the methodology used by Beale et al. Using assumptions about the primary endpoint, the analysis indicated that a sample size of 41 in each group is required to differentiate between the two groups with slopes similar to that reported by Beale et al., that is a change in slope from (−0.15) under the null hypothesis to (−0.30) under the alternative hypothesis when the SD of the mean is 3.00, the SD of the residuals is 1.00, and the two-sided significance level is 0.05. Allowing for dropouts, 88 patients will be recruited.

Statistical analysis
Statistical analysis will be performed using PASW software version 19.0 (SPSS). A baseline comparison of demographics, severity of illness and baseline measures will be carried out between each group, using a combination of Student t tests and χ² tests. Dichotomous data
(infectious complications, ICU mortality, and 60-day mortality) will be compared between groups using the \( \chi^2 \) test. Normally distributed continuous data will be analysed by a parametric test (ie, Student \( t \) test or ANOVA) and reported as mean±SD. Non-normally distributed continuous data will be analyzed with an appropriate non-parametric test (eg, Mann–Whitney \( U \) test) and reported as median\( \pm \)IQR. Data will be analyzed on the basis of intention-to-treat analysis (as per randomisation) and per protocol analysis for patients who receive at least 5 days’ supplementation. The differences will be considered statistically significant at \( p<0.05 \). An intention-to-treat analysis using a carry-forward analysis for missing data will be performed for all participants including withdrawn patients.

**MONITORING**

Regular team meetings will be held. The principal investigator, coinvestigators and other researchers will review study progress at these meetings, address pertinent issues and identify further actions to be taken. The principal investigator will ensure via this regular review process that data are managed appropriately (ie, stored in ‘potentially reidentifiable’ fashion) and that appropriate steps are taken with regard to data cleansing and dissemination of results. Also, an independent Data Monitoring Committee will monitor patients’ safety and treatment efficacy data while the trial is ongoing. This committee is independent of the sponsor and investigators, and has no competing interests.

**CONFIDENTIALITY AND PRIVACY**

Participants will not be identified by name, and confidentiality of the information in the medical report will be preserved. The information on subjects will be stored in both paper copies, on computer and on a CD in a coded manner. The data will be stored in a locked filing cabinet in a locked office. The computer will be password-protected. The data will be stored for 15 years and disposed after this period in a confidential shredder.

**STUDY TERMINATION**

There is no plan for early trial termination. The study will be considered terminated upon completion of all patient treatments and evaluations. If an interim analysis is carried out, Bonferroni corrections will be applied in the final stage (ie, significance \( p<0.05 \) will be changed to \( p<0.025 \), which will require a doubling of the number of subjects). However, there is no plan to carry out any interim analyses.

**ADVERSE EVENTS REPORTING**

All serious adverse events (SAEs) that are thought to be related to treatment are subject to expedited reporting and will be reported within 24 h. The principal investigator will be responsible for follow-up of all SAEs to ensure all details are available. The principal investigator will be responsible for reporting to the regulatory authorities (Therapeutic Goods Administration in Australia), the study supplement manufacturer (Fresenius Kabi), the Royal Brisbane and Women’s Hospital Ethics Committee, and University of Queensland ethics committee all SAE events that occur in the study.

**DISCUSSION**

This proposed trial with other worldwide trials will have implications in improving the practice of glutamine supplementation in critically ill patients. However, the results of this trial will only be relevant to trauma patients receiving enteral nutrition. It may not be directly applicable to other critically ill patients. The data for this study will not be applicable to trauma patients with severe renal failure or hepatic impairment.

This trial is a single-centre trial, so it is not powered to investigate the effect of intravenous alanyl-glutamine supplementation on mortality. This study will not be assessing underlying immunological or inflammatory changes, so the exact mechanism of any beneficial effects will not be clearly understood. Long-term outcomes are not assessed in this trial.

However, this trial is the first to investigate the effect of intravenous alanyl-glutamine supplementation in multiple trauma patients receiving enteral nutrition on organ dysfunction, infectious complications and body composition. We anticipate that the data from this study will add to the current practices of intravenous glutamine supplementation in trauma patients.

**Author affiliations**

1The University of Queensland, School of Medicine, Bums, Trauma & Critical Care Research Centre, Brisbane, Australia
2Department of Intensive Care Medicine, Royal Brisbane & Women’s Hospital, Brisbane, Australia
3Department of Nutrition and Dietetics, Royal Brisbane & Women’s Hospital, Brisbane, Australia

**Acknowledgements** We gratefully acknowledge the contribution of Fresenius Kabi, Bad Homburg, Germany for facilitating the provision of Dippeptiven. We thank S Adnan and J Varghese for assistance.

**Funding** This trial is supported by a grant from Royal Brisbane Women’s Hospital Foundation.

**Competing interests** Fresenius Kabi has a non-commercial interest in the project. Fresenius Kabi and Royal Brisbane Women’s Hospital foundation have no role in the protocol design and will not be involved in the analysis or interpretation of data.

**Ethics approval** Ethics approval was provided by the Human Ethics Committee of Royal Brisbane Women’s Hospital (protocol number: HREC/10/QRBW/131) and the University of Queensland Human Ethics Committee (Project No 2010001359).

**Contributors** RMA developed the study concept. RMA, JP, JC and MB developed the study design and protocol. JD provided statistical advice and will be involved in statistical consultation. JL provided advice and input to the study. JR will be coordinating the randomisation and preparation of study solutions. RMA drafted the manuscript. All authors contributed to the final manuscript.

**Provenance and peer review** Not commissioned; externally peer reviewed.


